Presentation is loading. Please wait.

Presentation is loading. Please wait.

Discussion of papers 3-4 and posters D-H, Session 1, CTOS, Prague, November 2012 Patrick Schöffski, Leuven, Belgium.

Similar presentations

Presentation on theme: "Discussion of papers 3-4 and posters D-H, Session 1, CTOS, Prague, November 2012 Patrick Schöffski, Leuven, Belgium."— Presentation transcript:

1 Discussion of papers 3-4 and posters D-H, Session 1, CTOS, Prague, November 2012 Patrick Schöffski, Leuven, Belgium

2 Instructions received from Program Chair A. discuss how presented data are going to change the landscape of sarcoma management today or tomorrow…

3 Preclinical work

4 ID , paper #3, p. 66 Simultaneous autophagy induction and inhibition induces cell death through necroptosis in sarcomas that lack argininosuccinate synthetase 1 expression Philip A. Boone et al., St. Louis, USA

5 Conflict of interest of discussant: – None Drug(s) tested: – Pegylated arginine delminase, an inhibitor of argininosuccinate synthase 1 (ASS 1), which is a key enzyme in the urea cycle Experimental concept: – Study involving tissue samples, cell lines and xenografts using immunohistochemistry, assays for cell proliferation and cell death Study aim(s): – To study the potential role of inhibition of ASS 1 in sarcoma models – Absence of ASS 1 associated with poor outcome in certain sarcomas Key results: – ASS 1 not expressed in 85 % of sarcomas: promising – Arginine depletion by pegylated arginine delminase arrests cell cycle – Simultaneous autophagy induction and inhibition by chloroquin induces cell death through necroptosis in enzyme-negative sarcomas Conclusions of authors: – Arginine depletion using pegylated arginine delminase may control tumor burden in sarcomas lacking ASS 1

6 Antiproliferative effects in MNNG/HOS ASS1 low osteosarcoma xenografts

7 Implications for the sarcoma community – New concept in sarcoma oncology: focusing on an absent molecular target – Clinical exploration of arginine depletion with pegylated arginine delminase +/- chloroquine (or related compounds that can be used in the clinic) warranted – Would suggest Phase 1 dose finding followed by disease-specific trial in ASS 1-negative bone and soft tissue sarcomas

8 ID , paper #4, p. 66 Y box binding protein 1 (YB-1): a novel hypoxic response integrated factor steering sarcoma cell invasion & metastatic dissemination Amal Mohammad El-Naggar et al., Vancouver, Canada

9 Drug(s) tested: – None Experimental concept: – Extensive preclinical study involving in vitro work, nude mice, zebrafish, genetically modified cells and various assays exploring cell motility and metastasis-promoting capacity of YB-1 Study aim(s): – To assess the potential role of YB-1 in sarcomas – YB-1 is a multifunctional cellular protein that mediates malignant transformation, cell migration and drug resistance, and is involved in epithelial-to-mesenchymal transition (EMT) Key results: – YB-1 found to contribute to sarcoma cell motility (likely through its downstream mediator HIF1a), invasion and metastasis Conclusions of authors: – YB-1 is a potential target for the treatment of metastatic sarcomas

10 Proposed mechanism for the interaction between YB-1 and HIF1a Tumor Progression YB-1 Hypoxic Induction HIF1α TranslationVEGF & neovascularization Metastatic Dissemination of sarcoma cells (Cap-independent Mechanism?)

11 Implications for the sarcoma community – No immediate implications as it is unclear whether YB-1 is druggable with specific agents – Methodological challenge: clinical trial designs to assess anti-migratory or anti-metastatic capacity of new treatments are far from being optimal

12 ID , poster H, p. 69 Trabectedin and PARP-1 inhibitors combination in preclinical models of bone and soft tissue sarcoma Ymera Pignochino et al., Torino, Italy

13 Drug(s) tested: – Trabectedin, a DNA-minor groove binder – Olaparib and veliparib as PARP inhibitors Experimental concept: – Preclinical study using cell lines of soft tissue and bone sarcomas, exploring the interaction between trabectedin and two PARP inhibitors Study aim(s): – To demonstrate in vitro-synergism between the minor groove binder and olaparib/veliparib Key results: – Trabectedin induces strong activation of PARP1 enzymatic activity in sarcoma cell lines – PARP1-inhibitors potentiate DNA damage induced by trabectedin Conclusions of authors: – Trabectedin and PARP-inhibitors show synergistic anti- proliferative effects in sarcoma cell lines, with induction of cell cycle arrest and apoptosis

14 3 How does trabectedin interact with PARP-I?

15 Implications for the sarcoma community – Would suggest a disease-specific Phase 1 study of trabectecin + PARP inhibitor (e.g. in sarcomas, breast cancer and ovarian cancer), involving sequential biopsies – Window-of-opportunity trial, e.g. in myxoid/ roundcell liposarcoma prior to surgery, with extensive pharmacodynamic tissue sampling – Bottleneck: availability of PARP-inhibitors

16 Clinical data

17 ID , poster D, p. 67 A phase II trial of novel anthracycline amrubicin in patients with advanced soft tissue sarcoma Launce G. Gouw et al., Salt Lake City, USA

18 Drug(s) tested: – Amrubicin Experimental concept: – Ongoing single-arm, open label Phase 2 trial in treatment- naive soft tissue sarcoma Study aim(s): – Clinical: to study RR, PFS, safety and toxicity, OS – Translational: genomic and proteomic biomarkers Key results: – AEs similar to experience with drug in other indications – No cardiotoxicity, no hematological toxicity – PR 25%, SD 58%, CBR 83% Conclusions of authors: – Well-tolerated and encouraging activity in sarcoma – Further studies warranted as single-agent or in combination

19 Tumor shrinkage and waterfall plot response surrogate (n=12)

20 Implications for the sarcoma community – Randomized trial(s) required to assess the added value of this anthracyclin as compared to established treatment standard doxorubicin – Drug competes with a number of other innovative anthracyclin derivatives (non-cardiotoxic, tumor- activated, temperature-activated prodrugs...) – Non-inferiority trial comparing with doxorubicin will unlikely satisfy regulatory agencies and will not be the most attractive design for investigators – Drug qualifies for combination trials given its good safety profile, e.g. Phase 1 combo with palifosfamide

21 The benchmark: EORTC trial HR = 0.83 (95.5% CI 0.67 – 1.03) p = HR = 0.74 (95% CI 0.60 – 0.90) p = Overall survival (primary endpoint) Progression-free survival Judson, Verweij, Gelderblom, Hartmann, Schöffski, Blay, dei Tos, Marreaud, Litiere, van der Graaf, ESMO Vienna 2012 Response rate: Doxorubicin 13.6 % Progression-free survival: Doxorubicin 4.6 mo (95% CI 2.9 – 5.6) Overall survival: Doxorubicin 12.8 mo (95.5 CI ) Survival at 1-year: Doxorubicin 51 % (95.5% CI 44-58)

22 ID , poster G, p. 69 Aldoxorubicin (INNO-206) is an active drug for the treatment of relapsed or refractory soft tissue sarcomas Sant Chawla et al., Los Angeles, USA

23 Drug(s) tested: – Aldoxorubicin (INNO-206) is a prodrug of doxorubicin that binds to albumin through a specific linker – Active compound released due to the acidic environment of the tumor Experimental concept: – Ongoing Phase 2 trial in sarcoma patients who failed prior chemo – Safety and efficacy of aldoxorubicin 350 mg/m2 (260 mg/m2 doxorubicin-equivalent) as single agent given i.v. q3w for up to 8 cycles Study aim(s): – To explore the safety and efficacy of aldoxorubicin in previously treated sarcoma patients Key results: – No relevant cardiotoxicity in patients exposed to high cumulative doses – Febrile neutropenia, sepsis and mucositis as SAEs Conclusions of authors: – High cumulative doses can be administered even in anthracyclin- pretreated patients, with evidence of antitumor efficacy

24 Waterfall plot response surrogate (n=13)

25 Implications for the sarcoma community – Randomized trial(s) required to assess the value of this anthracyclin as compared to doxorubicin in first line – Alternative strategy to explore the drug in patients progressing after previous response to doxorubicin – Drug competes with other innovative anthracyclin derivatives in the first line setting, and regulators will likely require more than a non-inferiority trial – In second line it would compete with trabectedin, pazopanib and a number of off label-treatments – Dose finding trial combining aldoxorubicin with palifosfamide to be considered as a strategic option

26 ID , poster E, p. 67 TH-302 maintenance following TH doxorubicine induction: the results of a phase 2 study Kristen N. Ganjoo et al., Stanford, USA

27 Drug(s) tested: – Doxorubicin + TH-302, a prodrug of the DNA-crosslinking alkylator bromo-isophosphoramide mustard, that releases the active moeity under hypoxic conditions Experimental concept: – Analysis of 48 patients who continued with maintenance TH-302 after having received up to 6 cycles of doxorubicin Study aim(s) – To explore the role of TH-302 maintenance Key results: – 53 % of patients entered maintenance period of Phase 2 trial after achieving CR, PR, SD, receiving TH-302 doses ranging between mg days 1+8 q3w – 5 SDs converted to PR, 1 PR converted to CR during maintenance Conclusions of authors: – Maintenance with TH-302 is well tolerated with limited hematological and manageable skin/mucosal toxicity; no cumulative toxicity during maintenance

28 Combining cytotoxic chemotherapy and hypoxia-activated TH-302

29 Implications for the sarcoma community – Supportive evidence for ongoing TH-CR-406/ SARC021 Phase 3 study comparing doxorubicin with doxorubicin/TH-302, which involves TH-302 maintenance (primary endpoint: overall survival) – Ongoing trial is performed in an increasingly competitive trial environment EORTC comparing doxorubicin with doxorubicin/ifosfamide failed to meet OS endpoint Phase 3 with doxorubicin vs. doxorubicin/palifosfamide already completed accrual (primary endpoint: PFS)

30 ID , poster F, p. 68 Phase I trial of abexinostat and doxorubicine in patients with metastatic sarcoma Edwin Choy et al., Boston, USA

31 Drug(s) tested: – Doxorubicin and abexinostat (PCI-24781), a HDAC inhibitor with preclinical activity in sarcoma cell lines and xenografts Experimental concept: – Phase 1b dose finding study of abexinostat combined with doxorubicin Study aim(s): – To identify MTD, safety, tolerability, PK and PD of abexinostat when administered on days 1-5 with doxorubicin 75 mg/m2 on day 4 q3w (+/- G-CSF ) in patients with advanced sarcoma Key results: – DLTs included grade 3 and 4 neuropenia without G-CSF grade 3 infection and grade 4 thrombocytopenia with G-CSF – In 17 participants evaluable for response there was 1 PR and 12 SD, and 7 patients continued >=5 cycles Conclusions of authors: – Abexinostat can be safely combined with full dose doxorubicin, toxicity is manageable with G-CSF support, clinical benefit seen

32 Most common AEs in Phase 1 trial combining abexinostat and doxorubicin

33 Implications for the sarcoma community – Drug combination could be explored in a randomized Phase 2 study, with doxorubicin as the standard arm, involving maintenance with the HDAC inhibitor – Is the evidence for HDAC inhibition in sarcoma strong enough to embark on large, expensive trials? – If Phase 2 would generate a convincing efficacy signal the consecutive registration trial would have to be performed in an increasingly competitive environment Outcome of Phase 3 with doxorubicin vs. doxorubicin/ palifosfamide likely reported at that point Phase 3 trial doxorubicin vs. doxorubicin/Th-302 likely completed accrual at that point

34 Congratulations to all authors and sponsors of the presented work

35 Please show your real excitement for all the good work presented in Session 1 Hypnosis conference

Download ppt "Discussion of papers 3-4 and posters D-H, Session 1, CTOS, Prague, November 2012 Patrick Schöffski, Leuven, Belgium."

Similar presentations

Ads by Google